Nine psychotic patients under continuous oral treatment with haloperidol were randomly given a test dose of 1.5–5 mg haloperidol orally and/or intravenously. Serum levels of haloperidol were determined by high performance liquid chromatography and serum concentration data obtained were submitted to pharmacokinetic analysis. The steady state concentration ratio between blood and plasma was determined and found to be 0.79±0.03. The blood clearance was then calculated to be 550±133 ml/min. The mean hepatic extraction ratio was intermediate (0.37). Consequently, for a drug mainly eliminated by hepatic metabolism like haloperidol, the total blood clearance and the extent of oral bioavailability can be affected by changes in hepatic blood flow, hepatic enzyme activities and drug binding. During continuous oral treatment with haloperidol, however, it can be shown that changes in the total metabolic capacity of the liver due to hepatic enzyme induction or inhibition should be important for the therapeutic effects of haloperidol. The volume of distribution at steady state (Vdss) was large (7.9±2.5 l/kg). The terminal half-life was 18.8 h after intravenous and 18.1 h after oral administration. The oral bioavailability (0.60±0.18) were in accordance with previous results in healthy subjects. A mean lag time after oral dose was 1.3±1.1 h and a longer absorption half-life (1.9±1.4 h) was found in the patients compared with healthy volunteers.
This is a preview of subscription content, log in to check access.
Buy single article
Instant access to the full article PDF.
Price includes VAT for USA
Subscribe to journal
Immediate online access to all issues from 2019. Subscription will auto renew annually.
This is the net price. Taxes to be calculated in checkout.
Benet LZ (1984) Pharmacokinetic parameters: which are necessary to define a drug substance? Eur J Respir Dis (Suppl) 134:45–61
Cressman WA, Bianchine JR, Slotnick VB, Johnson PC, Plostnieks J (1974) Plasma level profile of haloperidol in man following intramuscular administration. Eur J Clin Pharmacol 7:99–103
Dahl SG (1986) Plasma level monitoring of antipsychotic drugs, clinical utility. Clin Pharmacokinet 11:36–61
Forsman A, Öhman R (1976) Pharmacokinetic studies on haloperidol in man. Curr Ther Res 20:319–336
Forsman A, Öhman R (1977a) Studies on serum protein binding of haloperidol. Curr Ther Res 21:245–255
Forsman A, Öhman R. (1977b) Applied pharmacokinetics of haloperidol in man. Curr Ther Res 21:396–411
Forsman A, Larsson M (1978) Metabolism of haloperidol. Curr Ther Res 24:567–569
Forsman A, Martensson E, Nyberg G, Öhman R (1974) A gas chromatographic method for determining haloperidol. Naunyn Schmiedeberg's Arch Pharmacol 286:113–124
Gillette JR (1971) Factors affecting drug metabolism. Ann NY Acad Sci 179:43–66
Holley FO, Magliozzi JR, Stanski DR, Lombrozo L, Hollister LE (1983) Haloperidol kinetics after oral and intravenous doses. Clin Pharmacol Ther 33:477–484
Magliozzi JR, Hollister LE (1985) Elimination half-life and bioavailability of haloperidol in schizophrenic patients. J Clin Psychiatry 46:20–21
Metzler CM, Elfring GL, McEwen AJ (1974) NONLIN. The Up-john Co., Kalamazoo, Michigan
Pang KS, Rowland M (1977) Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 5:625–653
Rowland M, Tozer TN (1980) Clinical pharmacokinetics, concepts and applications. Lea and Febiger, Philadelphia
SAS Institute Inc, User's Guide (1979), North Carolina
About this article
Cite this article
Cheng, Y.F., Paalzow, L.K., Bondesson, U. et al. Pharmacokinetics of haloperidol in psychotic patients. Psychopharmacology 91, 410–414 (1987). https://doi.org/10.1007/BF00216005
- Psychotic patients
- Serum levels
- High performance liquid chromatography